Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma

被引:300
作者
Janot, Francois [1 ]
de Raucourt, Dominique
Benhamou, Ellen
Ferron, Christophe
Dolivet, Gilles
Bensadoun, Rene-Jean
Hamoir, Marc
Gery, Bernard
Julieron, Morbize
Castaing, Marine
Bardet, Etienne
Gregoire, Vincent
Bourhis, Jean
机构
[1] Inst Gustave Roussy, Villejuif, France
关键词
D O I
10.1200/JCO.2007.15.0102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity. The Groupe d'Etude des Tumeurs de la Tete et du Cou and Groupe d'Oncologie Radiotherapie Tete Et Cou groups performed a randomized study to assess its efficacy. Patients and Methods Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation (a "wait and see" approach; WS arm). Eligibility criteria were recurrence or a second primary tumor in a previously irradiated area, no major sequelae resulting from the first radiotherapy, good general condition, no distant metastasis, and salvage surgery with macroscopic complete resection. Patients in the RT arm received 60 Gy over 11 weeks combined with concomitant fluorouracil and hydroxyurea. Results Sixty-five patients were randomly assigned to each arm. There was no imbalance in the distribution of the main tumor and patients characteristics. The most serious acute toxicity in the RT arm was mucositis, attaining grade 3 or 4 in 28% of patients. At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P=.06). Disease-free survival (DFS) was significantly improved in the RT arm, with a hazard ratio of 1.68 (95% CI, 1.13 to 2.50; P = .01), but overall survival ( OS) was not statistically different. Conclusion Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS. An increase in both acute and late toxicity was observed.
引用
收藏
页码:5518 / 5523
页数:6
相关论文
共 19 条
[1]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[2]   Hyperfractionated or accelerated radiotherapy in head and neck cancer:: a meta-analysis [J].
Bourhis, Jean ;
Overgaard, Jens ;
Audry, Helene ;
Ang, Kian K. ;
Saunders, Michele ;
Bernier, Jacques ;
Horiot, Jean-Claude ;
Le Maitre, Aurlie ;
Pajak, Thomas F. ;
Paulsen, Michael G. ;
O'Sullivan, Brian ;
Dobrowsky, Werner ;
Hliniak, Andrzej ;
Skladowski, Krzysztof ;
Hay, John H. ;
Pinto, Luiz H. J. ;
Fallai, Carlo ;
Fu, Karen K. ;
Sylvester, Richard ;
Pignon, Jean-Pierre .
LANCET, 2006, 368 (9538) :843-854
[3]  
Chen Yi-Jen, 2002, Med Dosim, V27, P171, DOI 10.1016/S0958-3947(02)00100-0
[4]   Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients [J].
De Crevoisier, R ;
Bourhis, J ;
Domenge, C ;
Wibault, P ;
Koscielny, S ;
Lusinchi, A ;
Mamelle, G ;
Janot, F ;
Julieron, M ;
Leridant, AM ;
Marandas, P ;
Armand, JP ;
Schwaab, G ;
Luboinski, B ;
Eschwege, F .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3556-3562
[5]  
De Crevoisier R, 2001, CANCER-AM CANCER SOC, V91, P2071, DOI 10.1002/1097-0142(20010601)91:11<2071::AID-CNCR1234>3.0.CO
[6]  
2-Z
[7]   SIMULTANEOUS CHEMORADIOTHERAPY AS SALVAGE TREATMENT IN LOCOREGIONAL RECURRENCES OF SQUAMOUS HEAD AND NECK-CANCER [J].
GANDIA, D ;
WIBAULT, P ;
GUILLOT, T ;
BENSMAINE, A ;
ARMAND, JP ;
MARANDAS, P ;
LUBOINSKI, B ;
CVITKOVIC, E .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1993, 15 (01) :8-15
[8]   Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease [J].
Haraf, DJ ;
Weichselbaum, RR ;
Vokes, EE .
ANNALS OF ONCOLOGY, 1996, 7 (09) :913-918
[9]   Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies [J].
Kramer, NM ;
Horwitz, EM ;
Cheng, J ;
Ridge, JA ;
Feigenberg, SJ ;
Cohen, RB ;
Nicolaou, N ;
Sherman, EJ ;
Babb, JS ;
Damsker, JA ;
Langer, CJ .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (05) :406-414
[10]   Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of radiation therapy oncology group protocol 9911 [J].
Langer, Corey J. ;
Harris, Jonathan ;
Horwitz, Eric M. ;
Nicolaou, Nicos ;
Kies, Merrill ;
Curran, Walter ;
Wong, Stuart ;
Ang, Kian .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4800-4805